Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Adaptive Biotechnologies Corporation is a biotechnology business based in the US. Adaptive Biotechnologies Corporation shares (ADPT) are listed on the NYSE and all prices are listed in US Dollars. Adaptive Biotechnologies Corporation employs 453 staff and has a trailing 12-month revenue of around USD$92.4 million.
|Latest market close||USD$46.93|
|52-week range||USD$15.19 - USD$65.69|
|50-day moving average||USD$55.7864|
|200-day moving average||USD$47.42|
|Wall St. target price||USD$62.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.344|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-22.15%|
|1 month (2020-12-16)||-17.19%|
|3 months (2020-10-16)||-9.21%|
|6 months (2020-07-16)||17.77%|
|1 year (2020-01-16)||71.47%|
|2 years (2019-01-12)||N/A|
|3 years (2018-01-12)||N/A|
|5 years (2016-01-12)||N/A|
Valuing Adaptive Biotechnologies Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptive Biotechnologies Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adaptive Biotechnologies Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 44x. In other words, Adaptive Biotechnologies Corporation shares trade at around 44x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||USD$92.4 million|
|Gross profit TTM||USD$-7,908,000|
|Return on assets TTM||-8.25%|
|Return on equity TTM||-17.97%|
|Market capitalisation||USD$8.5 billion|
TTM: trailing 12 months
There are currently 3.9 million Adaptive Biotechnologies Corporation shares held short by investors – that's known as Adaptive Biotechnologies Corporation's "short interest". This figure is 46.1% down from 7.2 million last month.
There are a few different ways that this level of interest in shorting Adaptive Biotechnologies Corporation shares can be evaluated.
Adaptive Biotechnologies Corporation's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies Corporation shares currently shorted divided by the average quantity of Adaptive Biotechnologies Corporation shares traded daily (recently around 817396.19450317). Adaptive Biotechnologies Corporation's SIR currently stands at 4.73. In other words for every 100,000 Adaptive Biotechnologies Corporation shares traded daily on the market, roughly 4730 shares are currently held short.
However Adaptive Biotechnologies Corporation's short interest can also be evaluated against the total number of Adaptive Biotechnologies Corporation shares, or, against the total number of tradable Adaptive Biotechnologies Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Adaptive Biotechnologies Corporation shares in existence, roughly 30 shares are currently held short) or 0.0569% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies Corporation shares, roughly 57 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies Corporation.
Find out more about how you can short Adaptive Biotechnologies Corporation stock.
We're not expecting Adaptive Biotechnologies Corporation to pay a dividend over the next 12 months.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.